| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 650.71M | 639.14M | 445.54M | 11.55M | 106.87M | 49.21M |
| Gross Profit | 424.02M | 415.29M | 273.01M | -67.21M | 24.62M | -30.39M |
| EBITDA | 236.88M | 240.18M | 152.80M | -141.61M | -83.86M | -140.97M |
| Net Income | -98.12M | -96.73M | -133.52M | -326.45M | -252.56M | -321.63M |
Balance Sheet | ||||||
| Total Assets | 2.92B | 2.99B | 3.24B | 3.59B | 3.32B | 3.07B |
| Cash, Cash Equivalents and Short-Term Investments | 97.83M | 127.63M | 228.04M | 509.52M | 499.29M | 573.24M |
| Total Debt | 2.18B | 2.18B | 2.35B | 2.45B | 2.10B | 1.60B |
| Total Liabilities | 2.30B | 2.34B | 2.51B | 2.72B | 2.37B | 1.78B |
| Stockholders Equity | 568.18M | 590.74M | 728.98M | 876.14M | 944.18M | 1.06B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 103.14M | -175.72M | -630.90M | -541.32M | -370.16M |
| Operating Cash Flow | 0.00 | 189.90M | -18.89M | -178.78M | -136.84M | -181.63M |
| Investing Cash Flow | 0.00 | -108.46M | -161.54M | -453.39M | -407.24M | -195.51M |
| Financing Cash Flow | 0.00 | -183.26M | -100.90M | 643.11M | 471.51M | 623.89M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $39.54B | 25.99 | 62.28% | 1.88% | 8.37% | 10.20% | |
| ― | $8.93B | 18.08 | 17.34% | ― | 0.89% | -31.56% | |
| ― | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
| ― | $216.44M | 3.68 | ― | ― | -4.95% | ― | |
| ― | $13.06B | 37.04 | ― | 0.80% | -1.94% | -53.90% | |
| ― | $874.47M | -12.27 | -11.87% | ― | 15.03% | 27.99% | |
| ― | $3.25B | 61.90 | ― | ― | 12.22% | ― |
On September 16, 2025, Studio City International Holdings Limited announced that its subsidiary, SCRS, entered into an agreement with iRad to operate a private hospital at the Studio City integrated resort. The agreement, effective from January 1, 2025, allows iRad to provide imaging and diagnostic services starting tentatively on October 1, 2025, until November 30, 2034, with options for renewal. This strategic move is part of the company’s commitment to supporting Macau’s healthcare industry and aligns with its broader operational goals.
On August 29, 2025, Studio City International Holdings Limited released its quarterly report for Studio City Finance Limited, covering the financial performance for the three and six months ending June 30, 2025. The report highlights the repayment of the 2025 Studio City Finance Notes, indicating a strategic move to manage its debt obligations. This financial maneuver could strengthen the company’s financial position and potentially improve its market standing, impacting stakeholders positively by reducing financial liabilities.
Studio City International Holdings reported a significant increase in its unaudited financial results for the second quarter of 2025, with total operating revenues reaching $190.1 million, up from $161.5 million in the same quarter of 2024. This growth was driven by improved performance in mass market operations and higher non-gaming revenues. The company also reported a notable reduction in net loss, which decreased to $3.7 million from $33.4 million in the previous year. The strategic shift away from VIP rolling chip operations to focus on mass market and premium mass operations has positively impacted the company’s financial performance.